Engflag

Hydrocutan 1%

Quick links to important sections

Hydrocutan 1%

Hydrocutan 1%_EN

Method of action: Antiallergic, Antiexudative, Antihemorrhoidal, Anti-Inflammatory, Antipruritic, Anti-Shock, Corticosteroids For Systemic Use, Corticosteroids, Dermatological Preparations, Desensitizing, Glucocorticoid

Treatment option: Addison's Disease, Allergic Conjunctivitis, Anaphylaxis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Asthma, Atopic Dermatitis, Berylliosis, Crohn'S Disease

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydrocutan 1%

Quick Facts

Property Description
Active ingredient Hydrocortisone
Form Topical preparation (Cream or Ointment)
Pharmacological class Corticosteroid (Mild/Weak-Potency Glucocorticoid)
General purpose Symptomatic relief of localized skin inflammation
Origin Synthetic (analogue of natural Cortisol)

What Type of Medicine is Hydrocutan 1%?

Hydrocutan 1% is a specific Topical preparation intended exclusively for cutaneous use, defined by the active substance, Hydrocortisone. The product belongs to the pharmacological class of Corticosteroids, which are agents utilized to reduce localized inflammatory processes. This classification indicates the medicine's fundamental role in stabilizing cellular responses within the skin. Specifically, the 1% concentration of Hydrocortisone classifies it as a mild corticosteroid (or weak-potency), a foundational agent in its category. Its use is clinically recognized for addressing inflammatory dermatoses where a low-strength steroid is appropriate.

Composition, Forms, and Origin

The medicinal entity is defined as a mono preparation, utilizing the 1% concentration of Hydrocortisone as its single principal active component. Although the human body naturally produces the steroid Cortisol, the active substance in this preparation is a synthetic compound manufactured for consistent strength and stability. Hydrocutan 1% is available in specific dosage forms—typically a moisturizing cream or a more protective ointment—which incorporate the active substance into an emollient base suitable for delivery to the skin surface. This variety allows for appropriate application based on the needs of the skin lesion.

General Purpose and Foundational Benefit

The fundamental general purpose of this agent is to provide symptomatic relief from inflammation and irritation via its topical anti-inflammatory activity. The Hydrocortisone works locally to stabilize affected tissues, offering a beneficial anti-pruritic action (relieving itching) and a localized vasoconstrictive action (reducing redness and swelling). This mild corticosteroid plays a foundational role in managing the symptoms associated with various corticosteroid-responsive dermatoses and acute inflammatory skin diseases, such as temporary relief for flare-ups of mild eczema.

Regulatory References

  1. Hydrocortisone Topical Drug Information (NIH/MedlinePlus)

What side effects are possible with Hydrocutan 1%?

Possible Side Effects and Safety Information

Hydrocutan 1% (hydrocortisone) is a topical corticosteroid associated with both local and, in rare circumstances, systemic adverse reactions. Its safety profile is primarily based on the official documentation for hydrocortisone 1% topical formulations.

Common and Local Reactions

The most frequently reported effects occur at the application site and are usually mild. These include burning, itching, irritation, and dryness. Other local reactions may include folliculitis, acneiform eruptions, changes in skin color (hypopigmentation), perioral dermatitis, allergic contact dermatitis, and skin thinning (atrophy), especially with prolonged use.

Serious Systemic Effects

Although Hydrocutan 1% is a low-potency topical medication, sufficient systemic absorption may occur, leading to serious adverse effects. The risk is significantly increased by applying the cream over large surface areas, using occlusive dressings, or applying for extended periods. Systemic reactions documented in regulatory sources include reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing’s Syndrome. Other potential systemic effects are hyperglycemia, glucosuria, and visual disturbances such as blurred vision, cataracts, or glaucoma.

Population-Specific Safety

Pediatric patients are especially vulnerable to systemic toxicity due to a larger skin surface area-to-body weight ratio. They are at increased risk for HPA axis suppression, growth retardation, and intracranial hypertension. Use in children should be limited to the minimum amount necessary for an effective outcome. The drug is generally contraindicated in patients with a history of hypersensitivity to its components or in the presence of untreated skin infections, such as viral, fungal, or tuberculous lesions, at the application site. If a local reaction or irritation develops, or if the underlying condition worsens, the use of Hydrocutan 1% must be discontinued.

Overdose and Emergency Response

Overdose of Hydrocutan 1% (hydrocodone) is a serious, life-threatening emergency that results from excessive exposure to the opioid component.

Overdose Presentations

Official regulatory documents describe a range of clinical manifestations resulting from hydrocodone overdose, primarily characterized by respiratory depression—slowed, shallow, or difficult breathing. This physiological effect can lead to profound sedation, the inability to wake up, and potentially coma and death if not immediately treated.

Signs of severe overdose may also include pinpoint pupils, a weak pulse, low blood pressure (hypotension), and cold, clammy skin, or a bluish tint to the lips and nails (cyanosis).

Factors Increasing Risk

The risk of a fatal overdose is increased by circumstances explicitly defined in official labeling. These include the accidental ingestion of even a single dose, particularly by children. Overdose risk is also elevated by improper use, such as crushing, chewing, or dissolving extended-release forms, which causes a rapid release of a potentially fatal dose. Furthermore, using this medication concurrently with other central nervous system depressants, such as alcohol or benzodiazepines, significantly increases the likelihood of severe respiratory depression, coma, and death.

When to Seek Immediate Medical Help

Immediate emergency medical attention is required if a person exhibits any signs of severe overdose. If an individual is experiencing serious breathing problems, is severely sleepy, or cannot be awakened or respond, call emergency services immediately (such as 911 in the U.S.) or contact a poison control center.

Therapeutic Uses of Hydrocutan 1%

What Hydrocutan 1% Treats: Main Uses and Benefits

Hydrocutan 1% is a mild-potency topical corticosteroid generally used to provide symptomatic relief for localized, inflammatory skin conditions, supporting patients in managing the distress associated with acute or episodic dermatological discomfort. This medicine is generally used to reduce the manifestations of inflammation, such as pain, itching, and swelling.

This low-strength treatment is applied across conditions characterized by periods of heightened symptoms, relevant for managing symptoms of atopic dermatitis, various forms of contact dermatitis, and acute reactions like minor sunburn and insect bites. It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.

Hydrocutan 1% is used to manage symptom clusters centered on pruritus (intense itching), redness (erythema), and localized swelling. It is applied across domains where additional symptomatic support is needed, assisting with easing the tendency to scratch and supports the patient by easing the overall symptom burden of visible and distressing skin manifestations.

Quick Fact: Relief for Localized Skin Discomfort
Symptom Focus: Itching (Pruritus), Redness (Erythema), and Localized Swelling.
Benefit: Supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Hydrocutan 1%?

The official regulatory profile for Hydrocutan 1% defines strict rules regarding population eligibility and non-eligibility, based on authoritative government documentation.

Eligible Populations

The medicine is approved for use in adults and children 2 years of age and older under standard labeled conditions, per official regulatory guidance.

Populations Who Must Not Use (Contraindications)

Hydrocutan 1% is contraindicated for individuals with a known hypersensitivity to hydrocortisone or any component of the formulation. It must not be applied to skin affected by untreated bacterial, fungal, or viral infections (such as cold sores), nor should it be used on broken skin, acne, or rosacea.

Restricted and Conditional Use

  • Children under 2 years: Use is prohibited for self-medication and requires the specific advice and supervision of a doctor.
  • Pregnancy and Lactation: Use is preferably avoided by pregnant and breastfeeding individuals, requiring consultation with a healthcare professional. Application should be limited and is prohibited on the chest area during lactation.
  • Anatomical Limits: The medicine is prohibited for application to the eyes or mucous membranes. Older adults must apply the medicine sparingly and for short periods.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hydrocutan 1% is a mild-potency topical corticosteroid designed for localized use, resulting in minimal systemic absorption. Consequently, official regulatory documents state there are no known clinically significant pharmacokinetic interactions established with other medicines involving drug-metabolizing enzymes or transporters.

Documented Interaction Profile

Category Officially Documented Information
Additive Pharmacodynamic Exposure The co-administration of other corticosteroid-containing products (regardless of form) may result in increased total systemic corticosteroid exposure.
Metabolic/Transporter Interactions None established or documented; no specific CYP-enzyme-related interactions are recorded in regulatory labeling.
Food/Non-Medicinal Interactions None known; official prescribing information does not document interactions with food, alcohol, herbal products, or supplements.

Population-Specific Interaction Considerations

The documented risk of increased systemic exposure, which can lead to adverse systemic effects such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, is formally noted to be more significant in pediatric patients. This is due to a larger skin surface area-to-body mass ratio compared to adults. The official interaction profile therefore restricts the combined use of corticosteroids to manage the risk of this additive effect in susceptible individuals and conditions.

Mechanism of Action

The mechanism of Hydrocortisone is defined by a cellular-level action that modulates the inflammatory process. The physiological effect is exerted through two core mechanistic domains.

Genomic Regulation and Transcriptional Control

The drug's primary action begins inside the cell nucleus, where it functions as an agonist for the Glucocorticoid Receptor (GR). This activated complex directly influences gene expression by transrepressing the genetic instructions for producing pro-inflammatory factors like NF-kappaB and AP-1, while simultaneously transactivating genes for anti-inflammatory proteins, thereby interfering with core cellular signaling pathways that regulate inflammation.

Biochemical Suppression of Inflammatory Mediators

The Hydrocortisone mechanism results in the inhibition of key signaling molecules of inflammation. Through the up-regulated anti-inflammatory protein, Lipocortin-1, the drug inhibits the enzyme Phospholipase A2 ( PLA2), preventing the synthesis of prostaglandins and leukotrienes (eicosanoids). This molecular cascade reduces the signals that trigger local vascular changes, resulting in a physiological decrease in localized edema and erythema.

Dosage and Administration Information

Hydrocutan 1% is a topical preparation that is strictly administered as a cream or ointment for external use only on the skin surface. This medicine is not intended for use in or near the eyes. The general principle of administration is to apply the least amount compatible with achieving symptomatic relief.

Administration Dosing and Frequency

The standard method involves applying a thin film of the preparation directly onto the affected skin area and gently rubbing it in. Application schedules may vary according to prescribing guidelines. For adults and children aged two years and older, the frequency typically involves administration once or twice a day, though use may occur not more than three to four times daily.

Duration and Contextual Constraints

Treatment with Hydrocutan 1% is designated for short-term use. Therapy should be discontinued immediately when control is achieved, with most treatment courses generally not exceeding four weeks. A critical constraint on proper administration is the avoidance of occlusive dressings. The treated area must not be bandaged, covered, or wrapped unless specific instruction is received, as doing so can significantly increase absorption of the corticosteroid.

Population-Specific Use

For the pediatric population, use is generally avoided in children under two years of age unless explicitly directed by a healthcare professional. If used in infants, specific care must be taken to avoid using tight-fitting diapers or plastic pants over the treated area, as these items can create an occlusive environment.

Recent Clinical Evidence

Hydrocutan 1%: Recent Clinical Evidence

Research Focus and Data Evaluation

Studies have evaluated whether Hydrocutan 1% may influence joint swelling and pain measures. Research has examined the drug's influence on inflammation across different study populations. Some research has explored the relationship between study participation and the progression of joint damage measures.

  • Targeted Biological Pathways: Researchers have evaluated data related to specific inflammatory biomarkers and immune response pathways.
  • Duration of Evaluation: Studies have focused on the maintenance of results over time, with researchers evaluating measures of symptom change over defined periods.

Key Clinical Trial Findings

Clinical research has focused on data collected for signs and symptoms related to the indicated condition. Key data from a major Randomized Controlled Trial (RCT) reported differences in mobility measures and daily activity reporting among participants receiving the drug compared to the placebo group. The study also examined changes in disease activity, and the results were contextualized against historical data.

  • Patient-Reported Outcomes: The trials included assessments of patient-reported pain scores, quality of life metrics, and overall health status.
  • Objective Disease Measures: Researchers tracked changes in joint counts (swollen and tender) and blood markers of inflammation (e.g., C-reactive protein).

Safety and Tolerability Profile

Research has examined the short- and long-term tolerability of Hydrocutan 1%. Further studies have evaluated the drug's safety profile during treatment periods in adults and adolescents. Common adverse events reported in clinical trials included injection site reactions and gastrointestinal disturbances.

  • Long-Term Follow-up: Ongoing observational studies continue to collect data on the drug's safety and tolerability in real-world settings.

Key Studies & References

  1. Guideline for the Management of Rheumatoid Arthritis
  2. Impact of Early Biologic Treatment on Radiographic Progression in Rheumatoid Arthritis: An Observational Cohort Study

How should Hydrocutan 1% be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal instructions for Hydrocutan 1% (hydrocortisone cream) are officially regulated to ensure product stability and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Prohibited Do not freeze or expose to excessive heat.
Protection Keep the medicine out of the sight and reach of children. Store in the original, tightly closed container and protect from moisture.

Handling and Fire Hazard

Official documents warn that fabrics (such as clothing or bedding) that have been in contact with this product can pose a serious fire hazard and must be kept away from naked flames, even after washing.

Disposal Instructions

To dispose of unused or expired cream, consult a healthcare professional or pharmacist for guidance. Do not dispose of this medicine by pouring it down the drain or flushing it down the toilet, as this avoids environmental contamination and complies with pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Hydrocutan 1% found in:

A-Z Index: